Membrane androgen receptor down-regulates c-Src-activity and beta-catenin transcription and triggers GSK-3beta-phosphorylation in colon tumor cells

Cellular Physiology and Biochemistry

Volumn 34, Issue 4, 2014, Pages 1402-1412

  Gu, Shuchen ^a,b   Honisch, Sabina ^a   Kounenidakis, Michalis ^c   Alkahtani, Saad ^c,d   Alarif, Saud ^d   Alevizopoulos, Konstantinos ^e   Stournaras, Christos ^a,c   Lang, Florian ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b ZHEJIANG UNIVERSITY   (China)

^c UNIVERSITY OF CRETE   (Greece)

^d KING SAUD UNIVERSITY   (Saudi Arabia)

^e Pharmacellion Ltd   (United Kingdom)

Author keywords

Actin; Beta catenin; c Src; Colon tumors; Cyclin D1; GSK 3beta; mARs

Indexed keywords

ANDROGEN RECEPTOR; BETA CATENIN; CYCLIN D1; GLYCOGEN SYNTHASE KINASE 3BETA; MEMBRANE ANDROGEN RECEPTOR; PROTEIN KINASE P60; UNCLASSIFIED DRUG; ALBUMINOID; AR PROTEIN, HUMAN; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TESTOSTERONE;

ARTICLE; CACO 2 CELL LINE; CARCINOGENIC ACTIVITY; COLON TUMOR; CONFOCAL MICROSCOPY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; ONCOGENE SRC; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING; ACTIN FILAMENT; APOPTOSIS; DOWN REGULATION; GENETICS; METABOLISM; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ACTIN CYTOSKELETON; ALBUMINS; APOPTOSIS; BETA CATENIN; CACO-2 CELLS; CELL LINE, TUMOR; COLONIC NEOPLASMS; DOWN-REGULATION; GENES, SRC; GLYCOGEN SYNTHASE KINASE 3; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TESTOSTERONE; TRANSCRIPTION, GENETIC;

EID: 84908620964     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000366346     Document Type: Article

References (51)

1. Kampa M, Papakonstanti EA, Hatzoglou A, Stathopoulos EN, Stournaras C, Castanas E: The human prostate cancer cell line LNCaP bears functional membrane testosterone receptors that increase PSA secretion and modify actin cytoskeleton. FASEB J 2002;16:1429-1431.
2. Papakonstanti EA, Kampa M, Castanas E, Stournaras C: A rapid, nongenomic, signaling pathway regulates the actin reorganization induced by activation of membrane testosterone receptors. Mol Endocrinol 2003;17:870-881.
3. Sen A, O'Malley K, Wang Z, Raj GV, Defranco DB, Hammes SR: Paxillin regulates androgen- and epidermal growth factor-induced MAPK signaling and cell proliferation in prostate cancer cells. J Biol Chem 2010;285:28787-28795.
4. Sun YH, Gao X, Tang YJ, Xu CL, Wang LH: Androgens induce increases in intracellular calcium via a G protein-coupled receptor in LNCaP prostate cancer cells. J Androl 2006;27:671-678.
5. Papadopoulou N, Papakonstanti EA, Kallergi G, Alevizopoulos K, Stournaras C: Membrane androgen receptor activation in prostate and breast tumor cells: molecular signaling and clinical impact. IUBMB Life 2009;61:56-61.
6. Kallergi G, Agelaki S, Markomanolaki H, Georgoulias V, Stournaras C: Activation of FAK/PI3K/Rac1 signaling controls actin reorganization and inhibits cell motility in human cancer cells. Cell Physiol Biochem 2007;20:977-986.
7. Kampa M, Nifli AP, Charalampopoulos I, Alexaki VI, Theodoropoulos PA, Stathopoulos EN, Gravanis A, Castanas E: Opposing effects of estradiol- and testosterone-membrane binding sites on T47D breast cancer cell apoptosis. Exp Cell Res 2005;307:41-51.
8. Gatson JW, Kaur P, Singh M: Dihydrotestosterone differentially modulates the mitogen-activated protein kinase and the phosphoinositide 3-kinase/Akt pathways through the nuclear and novel membrane androgen receptor in C6 cells. Endocrinology 2006;147:2028-2034.
9. Gu S, Papadopoulou N, Gehring EM, Nasir O, Dimas K, Bhavsar SK, Foller M, Alevizopoulos K, Lang F, Stournaras C: Functional membrane androgen receptors in colon tumors trigger pro-apoptotic responses in vitro and reduce drastically tumor incidence in vivo. Mol Cancer 2009;8:114.
10. Gu S, Papadopoulou N, Nasir O, Foller M, Alevizopoulos K, Lang F, Stournaras C: Activation of membrane androgen receptors in colon cancer inhibits the prosurvival signals Akt/bad in vitro and in vivo and blocks migration via vinculin/actin signaling. Mol Med 2011;17:48-58.
11. Gu S, Kounenidakis M, Schmidt EM, Deshpande D, Alkahtani S, Alarifi S, Foller M, Alevizopoulos K, Lang F, Stournaras C: Rapid activation of FAK/mTOR/p70S6K/PAK1-signaling controls the early testosterone-induced actin reorganization in colon cancer cells. Cell Signal 2013;25:66-73.
12. Lang F, Alevizopoulos K, Stournaras C: Targeting membrane androgen receptors in tumors. Expert Opin Ther Targets 2013;17:951-963.
13. Fonar Y, Frank D: FAK and WNT signaling: the meeting of two pathways in cancer and development. Anticancer Agents Med Chem 2011;11:600-606.
14. Gargalionis AN, Karamouzis MV, Papavassiliou AG: The molecular rationale of Src inhibition in colorectal carcinomas. Int J Cancer 2013;10.1002/ijc.28299
15. Russello SV, Shore SK: SRC in human carcinogenesis. Front Biosci 2004;9:139-144.
16. Tenbaum SP, Ordonez-Moran P, Puig I, Chicote I, Arques O, Landolfi S, Fernandez Y, Herance JR, Gispert JD, Mendizabal L, Aguilar S, Ramon y Cajal S, Schwartz S, Jr., Vivancos A, Espin E, Rojas S, Baselga J, Tabernero J, Munoz A, Palmer HG: beta-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nat Med 2012;18:892-901.
17. Jope RS, Johnson GV: The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 2004;29:95-102.
18. Beaulieu JM, Del'guidice T, Sotnikova TD, Lemasson M, Gainetdinov RR: Beyond cAMP: The Regulation of Akt and GSK3 by Dopamine Receptors. Front Mol Neurosci 2011;4:38.
19. Liang J, Slingerland JM: Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2003;2:339-345.
20. Fuchs SY, Ougolkov AV, Spiegelman VS, Minamoto T: Oncogenic beta-catenin signaling networks in colorectal cancer. Cell Cycle 2005;4:1522-1539.
21. Lang F, Perrotti N, Stournaras C: Colorectal carcinoma cells - regulation of survival and growth by SGK1. Int J Biochem Cell Biol 2010;42:1571-1575.
22. Tetsu O, McCormick F: Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999;398:422-426.
23. Lee MH, Padmashali R, Koria P, Andreadis ST: JNK regulates binding of alpha-catenin to adherens junctions and cell-cell adhesion. FASEB J 2011;25:613-623.
24. Tao YS, Edwards RA, Tubb B, Wang S, Bryan J, McCrea PD: beta-Catenin associates with the actin-bundling protein fascin in a noncadherin complex. J Cell Biol 1996;134:1271-1281.
25. Noritake J, Fukata M, Sato K, Nakagawa M, Watanabe T, Izumi N, Wang S, Fukata Y, Kaibuchi K: Positive role of IQGAP1, an effector of Rac1, in actin-meshwork formation at sites of cell-cell contact. Mol Biol Cell 2004;15:1065-1076.
26. Wagner EF, Nebreda AR: Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 2009;9:537-549.
27. Pelekanou V, Notas G, Sanidas E, Tsapis A, Castanas E, Kampa M: Testosterone membrane-initiated action in breast cancer cells: Interaction with the androgen signaling pathway and EPOR. Mol Oncol 2010;4:135-149.
28. Windham TC, Parikh NU, Siwak DR, Summy JM, McConkey DJ, Kraker AJ, Gallick GE: Src activation regulates anoikis in human colon tumor cell lines. Oncogene 2002;21:7797-7807.
29. Lu Y, Yu Q, Liu JH, Zhang J, Wang H, Koul D, McMurray JS, Fang X, Yung WK, Siminovitch KA, Mills GB: Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades. J Biol Chem 2003;278:40057-40066.
30. Guarino M: Src signaling in cancer invasion. J Cell Physiol 2010;223:14-26.
31. Sirvent A, Benistant C, Roche S: Oncogenic signaling by tyrosine kinases of the SRC family in advanced colorectal cancer. Am J Cancer Res 2012;2:357-371.
32. Mahajan K, Mahajan NP: PI3K-independent AKT activation in cancers: a treasure trove for novel therapeutics. J Cell Physiol 2012;227:3178-3184.
33. Schmidt EM, Gu S, Anagnostopoulou V, Alevizopoulos K, Foller M, Lang F, Stournaras C: Serum- and glucocorticoid-dependent kinase-1-induced cell migration is dependent on vinculin and regulated by the membrane androgen receptor. FEBS J 2012;279:1231-1242.
34. Morin PJ: beta-catenin signaling and cancer. Bioessays 1999;21:1021-1030.
35. Edlund S, Lee SY, Grimsby S, Zhang S, Aspenstrom P, Heldin CH, Landstrom M: Interaction between Smad7 and beta-catenin: importance for transforming growth factor beta-induced apoptosis. Mol Cell Biol 2005;25:1475-1488.
36. Sherr CJ: Cancer cell cycles. Science 1996;274:1672-1677.
37. Klein EA, Assoian RK: Transcriptional regulation of the cyclin D1 gene at a glance. J Cell Sci 2008;121:3853-3857.
38. Gotoh J, Obata M, Yoshie M, Kasai S, Ogawa K: Cyclin D1 over-expression correlates with beta-catenin activation, but not with H-ras mutations, and phosphorylation of Akt, GSK3 beta and ERK1/2 in mouse hepatic carcinogenesis. Carcinogenesis 2003;24:435-442.
39. Stournaras C, Gravanis A, Margioris AN, Lang F: The actin cytoskeleton in rapid steroid hormone actions. Cytoskeleton (Hoboken) 2014;10.1002/cm.21172
40. Mills CN, Nowsheen S, Bonner JA, Yang ES: Emerging roles of glycogen synthase kinase 3 in the treatment of brain tumors. Front Mol Neurosci 2011;4:47.
41. Miyashita K, Nakada M, Shakoori A, Ishigaki Y, Shimasaki T, Motoo Y, Kawakami K, Minamoto T: An emerging strategy for cancer treatment targeting aberrant glycogen synthase kinase 3 beta. Anticancer Agents Med Chem 2009;9:1114-1122.
42. Watcharasit P, Bijur GN, Zmijewski JW, Song L, Zmijewska A, Chen X, Johnson GV, Jope RS: Direct, activating interaction between glycogen synthase kinase-3beta and p53 after DNA damage. Proc Natl Acad Sci U S A 2002;99:7951-7955.
43. Grimes CA, Jope RS: CREB DNA binding activity is inhibited by glycogen synthase kinase-3 beta and facilitated by lithium. J Neurochem 2001;78:1219-1232.
44. Beurel E, Jope RS: The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog Neurobiol 2006;79:173-189.
45. Mishra R: Glycogen synthase kinase 3 beta: can it be a target for oral cancer. Mol Cancer 2010;9:144.
46. Takahashi-Yanaga F: Activator or inhibitor? GSK-3 as a new drug target. Biochem Pharmacol 2013;86:191-199.
47. Menon B, Johnson JN, Ross RS, Singh M, Singh K: Glycogen synthase kinase-3beta plays a pro-apoptotic role in beta-adrenergic receptor-stimulated apoptosis in adult rat ventricular myocytes: Role of beta1 integrins. J Mol Cell Cardiol 2007;42:653-661.
48. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA: Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995;378:785-789.
49. Hetman M, Cavanaugh JE, Kimelman D, Xia Z: Role of glycogen synthase kinase-3beta in neuronal apoptosis induced by trophic withdrawal. J Neurosci 2000;20:2567-2574.
50. Pap M, Cooper GM: Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-Kinase/Akt cell survival pathway. J Biol Chem 1998;273:19929-19932.
51. Rubinfeld B, Albert I, Porfiri E, Fiol C, Munemitsu S, Polakis P: Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. Science 1996;272:1023-1026.